Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Allo-SCT for Multiple Myeloma
NCT02447055Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in multiple myeloma (MM), sponsored by Washington University School of Medicine. Primary endpoint: Safety and tolerability of regimen as measured by grade and frequency of adverse events. Planned start Dec 2015; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02447055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447055.